MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Akciju saraksts・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Slēgts

30.83 1.65

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

29.65

Max

31.07

Galvenie mērījumi
By Trading Economics
Ienākumi	-30M -30M
Pārdošana	-26M 77M
Peļņas marža	-38.823
Darbinieki	524
EBITDA	-12M -8M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+118.08% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-179M 1.5B
Iepriekšējā atvēršanas cena	29.18
Iepriekšējā slēgšanas cena	30.83

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

27.895 / 30.16 Atbalsts un pretestība

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. apr. 22:56 UTC

Galvenie ziņu notikumi

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

2026. g. 1. apr. 20:50 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

2026. g. 1. apr. 23:55 UTC

Tirgus saruna

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

2026. g. 1. apr. 23:43 UTC

Tirgus saruna

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

2026. g. 1. apr. 23:23 UTC

Galvenie ziņu notikumi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

2026. g. 1. apr. 23:07 UTC

Peļņas

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

2026. g. 1. apr. 23:02 UTC

Galvenie ziņu notikumi

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

2026. g. 1. apr. 23:00 UTC

Galvenie ziņu notikumi

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

2026. g. 1. apr. 22:39 UTC

Peļņas

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

2026. g. 1. apr. 22:08 UTC

Tirgus saruna

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

2026. g. 1. apr. 22:00 UTC

Galvenie ziņu notikumi

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

2026. g. 1. apr. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

2026. g. 1. apr. 21:31 UTC

Galvenie ziņu notikumi

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

2026. g. 1. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 1. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 1. apr. 20:38 UTC

Peļņas

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

2026. g. 1. apr. 20:31 UTC

Iegādes, apvienošanās, pārņemšana

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

2026. g. 1. apr. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

2026. g. 1. apr. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

2026. g. 1. apr. 20:13 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Extends Tender Offer To Acquire Arcellx >GILD

2026. g. 1. apr. 20:07 UTC

Tirgus saruna

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

2026. g. 1. apr. 20:07 UTC

Iegādes, apvienošanās, pārņemšana

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

118.08% augšup

Prognoze 12 mēnešiem

Vidējais 65.75 USD 118.08%

Augstākais 100 USD

Zemākais 38 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.